Bhageeradh H Mulpur1, L Burt Nabors1, Reid C Thompson1, Jeffrey J Olson1, Renato V LaRocca1, Zachary Thompson1, Kathleen M Egan1. 1. Division of Neuro-Oncology , University of Alabama at Birmingham , Birmingham, Alabama (B.H.M., L.B.N.); Department of Neurosurgery , Vanderbilt University Medical Center , Nashville, Tennessee (R.C.T.); Department of Neurosurgery , Emory University School of Medicine , Atlanta, Georgia (J.J.O.); Norton Cancer Institute, Norton Healthcare , Louisville, Kentucky (R.V.L.); Department of Cancer Epidemiology , H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida (Z.T., K.M.E.).
Abstract
BACKGROUND: Complementary therapy (CAM) is common in cancer patients. We undertook this study to assess the association of complementary therapy usage with mortality in glioblastoma (GBM) patients. METHODS: The analysis was based on 470 patients. Information on current use of CAM was collected in structured interviews conducted a median of 6 weeks following GBM diagnosis. Proportional hazards regression was used to estimate hazard ratios (HRs) for GBM-related death according to the use of individual supplements with multivariate adjustment for known prognostic factors including age, KPS, and extent of tumor resection (ESR). RESULTS: Use of CAM agents was common, with 77% of the cohort reporting CAM usage. No mortality association was observed with the use of multivitamins (HR = 0.91; P = .40) or omega-3 fatty acids (HR = 1.07; P = .69). Patients taking vitamin D as an individual supplement (containing higher dosages than in a multivitamin) had reduced mortality when compared with nonusers (age-adjusted HR = 0.68; P = .02). However, the association was diminished after adjustment for KPS and ESR (HR = 0.74; P = .09). Use of herbal supplements was also associated with reduced mortality (HR = 0.58; P = .04). Vitamin E users had a nonsignificantly higher mortality when compared with nonusers (HR = 1.54; P = .09). CONCLUSIONS: Use of CAM is common in GBM patients. These exploratory analyses suggest no mortality association with the use of multivitamins or omega-3 fatty acids. Associations observed with vitamins D and E merit further investigation.
BACKGROUND: Complementary therapy (CAM) is common in cancerpatients. We undertook this study to assess the association of complementary therapy usage with mortality in glioblastoma (GBM) patients. METHODS: The analysis was based on 470 patients. Information on current use of CAM was collected in structured interviews conducted a median of 6 weeks following GBM diagnosis. Proportional hazards regression was used to estimate hazard ratios (HRs) for GBM-related death according to the use of individual supplements with multivariate adjustment for known prognostic factors including age, KPS, and extent of tumor resection (ESR). RESULTS: Use of CAM agents was common, with 77% of the cohort reporting CAM usage. No mortality association was observed with the use of multivitamins (HR = 0.91; P = .40) or omega-3 fatty acids (HR = 1.07; P = .69). Patients taking vitamin D as an individual supplement (containing higher dosages than in a multivitamin) had reduced mortality when compared with nonusers (age-adjusted HR = 0.68; P = .02). However, the association was diminished after adjustment for KPS and ESR (HR = 0.74; P = .09). Use of herbal supplements was also associated with reduced mortality (HR = 0.58; P = .04). Vitamin E users had a nonsignificantly higher mortality when compared with nonusers (HR = 1.54; P = .09). CONCLUSIONS: Use of CAM is common in GBM patients. These exploratory analyses suggest no mortality association with the use of multivitamins or omega-3 fatty acids. Associations observed with vitamins D and E merit further investigation.
Authors: Brian D Lawenda; Kara M Kelly; Elena J Ladas; Stephen M Sagar; Andrew Vickers; Jeffrey B Blumberg Journal: J Natl Cancer Inst Date: 2008-05-27 Impact factor: 13.506
Authors: Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi Journal: Clin Cancer Res Date: 2011-07-07 Impact factor: 12.531
Authors: Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert Journal: Brain Date: 2007-09-04 Impact factor: 13.501
Authors: Susobhan Sarkar; Axinia Döring; Franz J Zemp; Claudia Silva; Xueqing Lun; Xiuling Wang; John Kelly; Walter Hader; Mark Hamilton; Philippe Mercier; Jeff F Dunn; Dave Kinniburgh; Nico van Rooijen; Stephen Robbins; Peter Forsyth; Gregory Cairncross; Samuel Weiss; V Wee Yong Journal: Ann Neurosci Date: 2013-10
Authors: Cheppail Ramachandran; Gilda M Portalatin; Adriana M Prado; Karl-Werner Quirin; Enrique Escalon; Steven J Melnick Journal: J Evid Based Complementary Altern Med Date: 2016-07-19